OncoMatch/Clinical Trials/NCT05294367
Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
Is NCT05294367 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Magnesium Chloride-based Lotion for lymphoma.
Treatment: Magnesium Chloride-based Lotion — This early phase I trial investigates the effect of dietary and topical magnesium replacement on magnesium blood levels in patients with lymphoma. Magnesium is an element in the body that is important to cell health. The body cannot make magnesium and it typically comes from the food we eat. In patients who are ill, magnesium is often replaced intravenously (IV) through a vein or by mouth. This study may help researchers find out if being on a magnesium rich diet and using a magnesium lotion on the skin helps to keep magnesium blood levels in an ideal range. This study also investigates side effects and quality of life when receiving different forms of magnesium.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: myelosuppressive chemotherapy
Exception: must be off with no planned chemotherapy for >= 2 months
If previously treated, the patient must be off myelosuppressive chemotherapy with no planned chemotherapy for >= 2 months
Cannot have received: magnesium supplements (magnesium oxide, intravenous magnesium)
Exception: multivitamin containing magnesium allowed if brand unchanged during study
Have taken dedicated magnesium supplements (i.e. magnesium oxide) or intravenous (IV) magnesium =< 28 days prior to pre-registration. Note: If patient is already on a multivitamin containing -magnesium, they may be enrolled, but the brand should not be changed during the 8 weeks on study
Cannot have received: antibiotics
Have taken antibiotics =< 7 days prior to pre-registration
Cannot have received: investigational agent
Receiving any other investigational agent for lymphoma or any other disease
Cannot have received: major surgery
Exception: diagnostic surgery allowed
Major surgery other than diagnostic surgery =< 4 weeks prior to pre-registration
Lab requirements
Kidney function
chronic kidney disease stage 3b or greater (eGFR < 45) excluded
patients with chronic kidney disease stage 3b or greater (estimated glomerular filtration rate [eGFR] < 45) will be excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify